Ware Rachel A, van Nagell John R
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Kentucky Chandler Medical Center and Markey Cancer Center, 800 Rose Street, Lexington, KY 40536-0293, USA.
Obstet Gynecol Int. 2010;2010. doi: 10.1155/2010/587610. Epub 2010 Sep 1.
Radical hysterectomy with pelvic lymphadenectomy remains the treatment of choice for women with Stages IA(2) and IB(1) carcinoma of the cervix, and selected patients with Stage II endometrial cancer. Improvement in surgical techniqe, administration of prophylactic antibiotics, thromboemolic prophylaxis, and advances in critical care medicine have resulted in lower operative morbidity associated with this procedure. Major urinary tract complications such as ureteral injury or vesico-vaginal fistula are now extremely rare (<1%). Five-year survival rates following this procedure vary according to a number of clinical and histologic variables, and may be as high as 90% in women without lymph node metastases.
根治性子宫切除术加盆腔淋巴结清扫术仍然是IA(2)期和IB(1)期宫颈癌女性以及部分II期子宫内膜癌患者的首选治疗方法。手术技术的改进、预防性抗生素的应用、血栓栓塞预防措施以及重症监护医学的进展,使得该手术相关的手术发病率降低。诸如输尿管损伤或膀胱阴道瘘等主要泌尿系统并发症现在极为罕见(<1%)。该手术后的五年生存率因多种临床和组织学变量而异,在无淋巴结转移的女性中可能高达90%。